Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Global Cord Blood Corporation, headquartered in Central, Hong Kong, primarily offers umbilical cord blood preservation and related support services within the People's Republic of China. The company's operations include the comprehensive testing, processing, and long-term storage of cord blood samples for its individual clients. Additionally, it undertakes the examination, preparation, and storage of donated cord blood units, facilitating their use for matching purposes. As of March 31, 2022, the corporation oversaw the management of three distinct cord blood banks, located in Beijing municipality, Guangdong province, and Zhejiang province. The entity previously operated as China Cord Blood Corporation, adopting its current name in March 2018, and functions as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is overpriced on P/E, of fair value o